No Detail Found!

Glimepiride study on type-2 diabetic subjects.

Author(s)
M. Zafar Iqbal Hydrie Baqi Institute of Diabetology and Endocrinology, Karachi, Pakistan
Asma Gull Baqi Institute of Diabetology and Endocrinology, Karachi, Pakistan
Rubina Hakeem Baqi Institute of Diabetology and Endocrinology, Karachi, Pakistan
M. Yagoob Ahmadani Baqi Institute of Diabetology and Endocrinology, Karachi, Pakistan
Abdul-Basit Baqi Institute of Diabetology and Endocrinology, Karachi, Pakistan
Abstract
The aim of the present study was to monitor the efficacy of glimepiride going beyond 4mg in our daily practice, since the action of glimepiride is reproducibly dose-dependent and the dose of glimepiride can be given upto 8 mg. This was a prospective study in which 113 subjects (56 Mates 57 Females) were recruited from the OPD of Baqai Institute of Diabetology and Endocrinology. The study started from 30t" October 2003 and the last subject was enrolled on 31St July 2004. Subjects having a HbAlc > 8 % on maximum dose of other Oral Hypoglycemic Agents (OHA) were given glimepiride six to eight milligrams and treatment followed up. HbAlc was rechecked after three to six months and this was taken as subjects reaching endpoint of the study. The mean baseline HbAl c of the patients was 10.17%. The patients were followed and HbA1 c done after an average of 5 months. The HbA1 c of subjects continuing on 6 mg of glimepiride (n= 103) was 8.73% while those on 8 mg (n=10) was 8.26%. The adjusted mean difference of HbAlc from baseline to 2nd sample for 6mg was -1.44% and for 8 mg was -1.91% which was statistically significant (p value
Publication Details
Page(s) 132-135
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 22, Issue: 2, Year: 2006

Request the full text from PASTIC

More from Pakistan Journal of Medical Sciences
0

Citations

0

Downloads

77

Views

Copyright ©  PASTIC National Center, Islamabad www.pastic.gov.pk